LA JOLLA PHARMACEUTICAL CO Form 8-K January 28, 2013

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# Form 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 01/28/2013

## LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

Commission File Number: 0-24274

CALIFORNIA

(State or other jurisdiction of incorporation)

33-0361285 (IRS Employer Identification No.)

4370 La Jolla Village Drive, Suite 400, San Diego, California 92122 (Address of principal executive offices, including zip code)

(858) 207-4264

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

#### Item 8.01. Other Events

On January 28, 2013, La Jolla Pharmaceutical Company (the "Company") issued a press release. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed with this report on Form 8-K:

Exhibit 99.1 Press Release dated January 28, 2013.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### LA JOLLA PHARMACEUTICAL COMPANY

Date: January 28, 2013

By: /s/ George Tidmarsh

George Tidmarsh President and Chief Executive Officer

## EXHIBIT INDEX

Exhibit No. Description

EX-99.1 Press Release Dated January 28, 2013